Logical Analysis Report

Key Focus

  • The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.
    The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv
  • Most patients reported pain at the injection site, which was mild to moderate, the company said, except in one of 12 subjects who received a 100 microgram dose, which was severe.
    The findings posted Wednesday have not been peer-reviewed yet
  • Pfizer shares jumped after it released positive results from its closely watched early-stage human trial on a coronavirus vaccine.
    The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.

To understand how to read this report, please click here

Knowledge Graph(Read more)

Complex Event Analysis(Read more)

High Level Topics

  • VACCINE
  • MICROGRAM
  • COVID-19
  • ANTIBODIES

    • High Level Abstractions

  • VACCINE(6, 0 Order)
  • ( VACCINE )(6, 0 Order)  top
  • ( VACCINE, MICROGRAM )(3, 1st Order)  top
  • ( VACCINE, COVID-19 )(2, 1st Order)  top
  • ( VACCINE, ANTIBODIES )(2, 1st Order)  top
  • ( VACCINE, WORLDWIDE )(1, 1st Order)  top
  • ( VACCINE, VIRUS )(1, 1st Order)  top
  • ( VACCINE, SCIENTISTS )(1, 1st Order)  top
  • ( VACCINE, PEER-REVIEWED )(1, 1st Order)  top
  • ( VACCINE, MEDRXIV )(1, 1st Order)  top
  • ( VACCINE, JOHNS_HOPKINS_UNIVERSITY )(1, 1st Order)  top
  • ( VACCINE, HEALTH )(2, 1st Order)  top
  • ( VACCINE, GLOBAL )(2, 1st Order)  top
  • ( VACCINE, EXPERTS )(1, 1st Order)  top
  • MICROGRAM(3, 0 Order)
  • ( MICROGRAM )(3, 0 Order)  top
  • COVID-19(3, 0 Order)
  • ( COVID-19 )(3, 0 Order)  top
  • ANTIBODIES(3, 0 Order)
  • ( ANTIBODIES )(3, 0 Order)  top

    • References

    • ( VACCINE )  top
    • ( VACCINE, MICROGRAM )  top
    • (Read more)   top. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.
    • (Read more)   top The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo.
      The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to...
    • (Read more)   top Most patients reported pain at the injection site, which was mild to moderate, the company said, except in one of 12 subjects who received a 100 microgram dose, which was severe.
      The findings posted Wednesday have not been peer-reviewed yet
    • ( VACCINE, COVID-19 )  top
    • (Read more)   top The effort by Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has infected more than 10 million people worldwide and killed at least 511,851, according to data compiled by Johns Hopkins University
    • (Read more)   topScientists conducting larger vaccine studies later this year hope to answer lingering questions about Covid-19 antibodies.
      Pfizer said it expects to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021
    • ( VACCINE, ANTIBODIES )  top
    • (Read more)   top
      The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was...
    • (Read more)   topScientists conducting larger vaccine studies later this year hope to answer lingering questions about Covid-19 antibodies.
      Pfizer said it expects to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021
    • ( VACCINE, WORLDWIDE )  top
    • (Read more)   top The effort by Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has infected more than 10 million people worldwide and killed at least 511,851, according to data compiled by Johns Hopkins University.
    • ( VACCINE, VIRUS )  top
    • (Read more)   top The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv
    • ( VACCINE, SCIENTISTS )  top
    • (Read more)   top
      Dr. Anthony Fauci, the nation's leading infectious disease expert, has said he is "cautiously optimistic" scientists can find a safe and effective vaccine by early 2021.
    • ( VACCINE, PEER-REVIEWED )  top
    • (Read more)   top
      The findings posted Wednesday have not been peer-reviewed yet.
      The effort by Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has infected more than 10 million people worldwide and killed at least 511,851,...
    • ( VACCINE, MEDRXIV )  top
    • (Read more)   top ... necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was posted in a paper released on MedRXiv.
    • ( VACCINE, JOHNS_HOPKINS_UNIVERSITY )  top
    • (Read more)   top ... Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has infected more than 10 million people worldwide and killed at least 511,851, according to data compiled by Johns Hopkins University.
    • ( VACCINE, HEALTH )  top
    • (Read more)   top"We are dedicated to develop potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency."
      The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany.
      The headquarters of German...
    • (Read more)   topDeveloping, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take years, global health experts say.
      Dr. Anthony Fauci, the nation's leading infectious disease expert, has said he is "cautiously optimistic" scientists can find a safe and effective vaccine by early...
    • ( VACCINE, GLOBAL )  top
    • (Read more)   top"We are dedicated to develop potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency."
      The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany.
      The headquarters of...
    • (Read more)   topDeveloping, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take years, global health experts say.
      Dr. Anthony Fauci, the nation's leading infectious disease expert, has said he is "cautiously optimistic" scientists can find a safe and effective vaccine by...
    • ( VACCINE, EXPERTS )  top
    • (Read more)   topDeveloping, testing and reviewing any potential vaccine is a long, complex and expensive endeavor that could take years, global health experts say.
      Dr. Anthony Fauci, the nation's leading infectious disease expert, has said he is "cautiously optimistic" scientists can find a safe and effective vaccine by early 2021
    • ( MICROGRAM )  top
    • (Read more)   top ... shares jumped after it released positive results from its closely watched early-stage human trial on a coronavirus vaccine. The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo. Pfizer said the vaccine was generally well-tolerated, though the experimental vaccine also caused fever in some patients, especially for those who were in the...
    • (Read more)   top The trial evaluated 45 people. Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo. The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity...
    • (Read more)   top ... an immune response to the virus. Pfizer said the vaccine was generally well tolerated, though the experimental vaccine caused fever in some patients, especially for those who were in the 100 microgram group. Most patients reported pain at the injection site, which was mild to moderate, the company said, except in one of 12 subjects who received a 100 microgram dose, which was severe. The...
    • ( COVID-19 )  top
    • (Read more)   top The effort by Pfizer and BioNTech is one of several working on a potential vaccine to prevent Covid-19, which has infected more than 10 million people worldwide and killed at least 511,851, according to data compiled by Johns Hopkins University
    • (Read more)   top ... has said he is "cautiously optimistic" scientists can find a safe and effective vaccine by early 2021. Scientists hope the antibodies provide some degree of protection against getting Covid-19, but they can't say that definitively yet since the virus was first discovered just six months ago
    • (Read more)   top Scientists conducting larger vaccine studies later this year hope to answer lingering questions about Covid-19 antibodies. Pfizer said it expects to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021
    • ( ANTIBODIES )  top
    • (Read more)   top Each participant received 10, 30 or 100 microgram doses of the vaccine or a placebo. The company said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses after 28 days, according to the preliminary data, which was...
    • (Read more)   top ... Anthony Fauci, the nation's leading infectious disease expert, has said he is "cautiously optimistic" scientists can find a safe and effective vaccine by early 2021. Scientists hope the antibodies provide some degree of protection against getting Covid-19, but they can't say that definitively yet since the virus was first discovered just six months ago
    • (Read more)   top Scientists conducting larger vaccine studies later this year hope to answer lingering questions about Covid-19 antibodies. Pfizer said it expects to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021